Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

Contributed by: ACCESS Newswire

Logo

Tags

Biotechnology

Lexaria Bioscience Corp.

NASDAQ:LEXX

NASDAQ:LEXXW

Company Update

More Like This

BioLife offers a new solution for oral GLP-1 delivery

BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

PR Newswire associated0

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

PR Newswire associated0

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

PR Newswire associated0

Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation